Methods for the treatment of nonHodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor

Details for Australian Patent Application No. 2011224166 (hide)

Owner Celgene Corporation

Inventors Schafer, Peter H.; Zhang, Ling-hua; Bartlett, J. Blake; Heise, Carla

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2011224166

PCT Pub. Number WO2011/112933

Priority 61/313,670 12.03.10 US

Filing date 11 March 2011

Wipo publication date 15 September 2011

International Classifications

A61K 31/45 - having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide

A61P 35/02 Antineoplastic agents

G01N 33/574 Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

4 October 2012 PCT application entered the National Phase

  PCT publication WO2011/112933 Priority application(s): WO2011/112933

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011224175-Anti-caking agent for flavored products

2011224165-Methods and systems for performing azimuthal simultaneous elatic inversion